drugset
drugset / Trial / NCT03104595

Management of Severe Chemotherapy-induced Neutropenia in Advanced Breast Cancer

NCT03104595 ↗

Phase 1/2 Completed 28 enrolled Enzychem Lifesciences Corporation
Non-randomizedSequentialOpen-labelTreatment

Summary

To assess the safety and establish the dose to assess the pharmacokinetic activity following administration of EC-18 in patients with advanced breast cancer receiving low febrile neutropenia risk chemotherapy who are the candidates for second-line or higher combination therapy with doxorubicin and cyclophosphamide.

Timeline

Start
2017-10-30
Primary completion
2019-11-26
Completion
2019-12-05

Drugs

EvaluationDrugModalityDoseRoute
Subject MOSEDIPIMOD Small molecule 500 mg Oral
Subject MOSEDIPIMOD Small molecule 1000 mg Oral
Subject MOSEDIPIMOD Small molecule 1500 mg Oral
Subject MOSEDIPIMOD Small molecule 2000 mg Oral
Subject MOSEDIPIMOD Small molecule 3000 mg Oral
Subject MOSEDIPIMOD Small molecule 4000 mg Oral

Indications

neutropenia